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Carbonic anhydrase IX (CA IX) is a transmembrane protein whose expression is strongly induced by hypoxia in a broad spectrum of
human tumours. It is a highly active enzyme functionally involved in both pH control and cell adhesion. Its presence in tumours usually
indicates poor prognosis. Ectodomain of CA IX is detectable in the culture medium and body fluids of cancer patients, but the
mechanism of its shedding has not been thoroughly investigated. Here, we analysed several cell lines with natural and ectopic
expression of CA IX to show that its ectodomain release is sensitive to metalloprotease inhibitor batimastat (BB-94) and that hypoxia
maintains the normal rate of basal shedding, thus leading to concomitant increase in cell-associated and extracellular CA IX levels.
Using CHO-M2 cells defective in shedding, we demonstrated that the basal CA IX ectodomain release does not require a functional
TNFa-converting enzyme (TACE/ADAM17), whereas the activation of CA IX shedding by both phorbol-12-myristate-13-acetate
and pervanadate is TACE-dependent. Our results suggest that the cleavage of CA IX ectodomain is a regulated process that
responds to physiological factors and signal transduction stimuli and may therefore contribute to adaptive changes in the protein
composition of tumour cells and their microenvironment.
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Carbonic anhydrases (CAs) are zinc metalloenzymes that catalyse a
reversible conversion of carbon dioxide to bicarbonate and proton
in a reaction: CO2þH2O2HCO3
 þH
þ. This simple reaction is
fundamental to physiological processes based on gas exchange, ion
transport and pH balance, such as respiration, production of body
fluids, digestion, bone resorption, renal acidification, etc. There-
fore, CAs are broadly distributed in various living organisms and
throughout the body in different tissues, cell types and subcellular
compartments (Pastorekova et al, 2004). Human CAs exist in at
least 15 isoforms, which involve 12 active isoenzymes: cytoplasmic
CA I, II, III, VII, XIII, mitochondrial CA VA and VB, secreted CA
VI and membrane-bound CA IV, IX, XII and XIV. The isoenzymes
exhibit variable catalytic activity, kinetic properties and sensitivity
to sulphonamide inhibitors (Supuran, 2004). Carbonic anhydrase
IX (CA IX, initially named MN or G250) is a highly active and
sulphonamide-avid isoform (Wingo et al, 2001; Vullo et al, 2003).
In contrast to other CA isoenzymes, CA IX is normally present in
only few normal tissues, namely in epithelia of the gastrointestinal
tract, whereas it is abnormally induced in various human tumours
including carcinomas of the kidney, lung, breast, colon, oeso-
phagus, breast, uterine cervix, etc. (Pastorekova and Zavada, 2004).
This tumour-associated distribution of CA IX is related to a strong
transcriptional activation of the CA9 gene by a hypoxia-inducible
factor 1, a key mediator of the molecular responses to low oxygen
supply (Wykoff et al, 2000). Accordingly, CA IX is predominantly
found in the perinecrotic hypoxic regions and signifies poor
prognosis (Potter and Harris, 2003). However, CA IX is not just a
surrogate marker of tumour hypoxia, but appears to be
functionally implicated in tumorigenesis via its capacity to
modulate cell adhesion and acidify the microenvironment of
hypoxic cells (Svastova et al, 2003, 2004).
Carbonic anhydrase IX is a type I membrane protein of 58/
54kDa. Its extracellular portion contains a large CA domain, which
is N-terminally extended with a proteoglycan (PG)-like region,
and via a single-pass transmembrane (TM) region is linked to a
short C-terminal intracytoplasmic (IC) tail (Pastorek et al, 1994;
Opavsky et al, 1996). The extracellular domain (ECD) of CA IX can
be released into the cell culture medium or into the body fluids of
tumour patients (Zavada et al, 2003). Concentration of CA IX ECD
in the blood and urine varies in a wide range and shows
no obvious correlation with the tumour size, at least in patients
with renal cell carcinomas. On the other hand, CA IX ECD is
cleared from the blood within a few days after nephrectomy and its
concentration in control individuals is extremely low (Zavada et al,
2003). Thus, it has been proposed that the detection of CA IX ECD
in the body fluids can find a clinical application in screening and
monitoring of tumour patients.
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sRecent evidence indicates that the ectodomain shedding is a
biologically relevant phenomenon, which affects the fate, location,
level and function of certain cytokines, growth factors, receptors,
cell-adhesion molecules, ectoenzymes, etc. It appears to occur at or
near the cell surface, generally depends upon the action of matrix
metalloproteinases (MMP) or adamalysins (ADAMs, for a disin-
tegrin and metalloproteinase) and can be often induced by phorbol
ester activators of protein kinase C (Arribas et al, 1996; Werb and
Yan, 1998; Schlondorff and Blobel, 1999).
Molecular mechanisms that underlie the release of CA IX ECD
have not been examined so far. Here, we analysed several cell lines
with natural and ectopic expression of CA IX for their capacity to
shed CA IX. We found that the CA IX ECD release is sensitive to
metalloproteinase inhibitor BB-94 and that hypoxia can retain a
normal rate of shedding producing more ECD concomitantly
with augmented expression of the protein in the cell. We also used
CHO cells, their shedding-defective mutant M2 cells and TACE-
transfected M2 cells to demonstrate that the constitutive CA IX
ectodomain release does not require functional TNFa-converting
enzyme (TACE/ADAM17), whereas induction of CA IX ECD
shedding by both phorbol-12-myristate-13-acetate and pervana-
date is TACE-dependent. Our results suggest that production of
CA IX ECD is a metalloprotease-mediated process that responds
to different signals and may therefore participate in adaptive
changes in the protein composition of tumour cells and of their
microenvironment.
MATERIALS AND METHODS
Cell lines and culture conditions
Tumour cell lines HeLa, SiHa, Caski (derived from cervical
carcinoma), HT-29 (colon carcinoma), ACHN (renal cell carci-
noma), CGL1 and CGL3 (hybrids between HeLa and normal
fibroblasts; Stanbridge et al, 1981) were grown in DMEM
(BioWhittaker, Verviers, Belgium) supplemented with 10% FCS,
at 371C in air with 5% CO2. The same culture conditions were
applied to MDCK canine kidney cells permanently transfected with
the full-length CA9 cDNA in pSG5C plasmid (MDCKþCA IX;
Svastova et al, 2003), to permanently transfected C33aþCA IX
cervical carcinoma cells, to Ka13 derivative of CHO-K1 Chinese
hamster cells lacking HIF-1a protein (kindly provided by Dr
Patrick Maxwell, Imperial College of Science, Technology and
Medicine, London, UK; Wood et al, 1998) and to CHO-WT, CHO-
M2, CHO-M2þTACE cells with normal, defective and over-
expressed TACE/ADAM17, respectively (Villanueva de la Torre
et al, 2004). The cells were exposed to hypoxia (2% O2)i na n
anaerobic workstation (Ruskin Technologies, Bridgend, UK) with
5% CO2, 10% H2 and 83% N2 at 371C. Transient transfection of
CHO-derived cell lines with the pSG5C-CA9 plasmid containing
the full-length CA9 cDNA (Pastorek et al, 1994) was performed
using the Gene Porter II transfection reagent according to the
instructions of the manufacturer (Gene Therapy Systems, San
Diego, CA, USA).
Antibodies and chemicals
M75 mouse monoclonal antibody (MAb) specific for the N-
terminal PG region of the CA IX protein and V/10 mouse MAb
specific for the CA domain of CA IX were described previously
(Pastorekova et al, 1992; Zatovicova et al, 2003). Purified M75 was
labelled with NHS-LC-Biotin (Pierce, Rockford, IL, USA) accord-
ing to the instructions of the manufacturer. Briefly, 2mg of
purified IgG dissolved in PBS, pH 8.0, were incubated with 100mg
NHS-LC-Biotin for 2h on ice. Free biotin was removed using
microconcentrator (PALL Gelman Lab., Wien, Austria) or gel
filtration. Secondary anti-mouse antibodies conjugated with
horseradish peroxidase were purchased from Sevapharma (Prague,
Czech Republic) and peroxidase-conjugated streptavidin was
obtained from Pierce (Rockford, IL).
Metalloprotease inhibitor BB-94 (batimastat; British Biotechno-
logy Ltd, Oxford, UK) and phorbol-12-myristate-13-acetate (PMA;
Sigma, St. Louis, MO) were dissolved in dimethyl sulphoxide
(DMSO) at 10mM, and stored in aliquots at  201C. Pervanadate
was prepared by mixing equimolar concentrations of orthovana-
date (Sigma) and H2O2 just before the experiment. Prior to use, the
inhibitors were diluted in culture medium to working concentra-
tions (1–10mM BB-94, 10mM PMA and 200mM pervanadate).
Recombinant epidermal growth factor (EGF; Austral Biologicals,
San Ramon, CA, USA) was used at 100ngml
 1 final concentration.
Biotinylation, immunoprecipitation and immunoblotting
Cells in monolayers of 70–80% confluence grown in a 6cm dish
were washed with ice-cold buffer A (20mM sodium hydrogen
carbonate, 0.15 M NaCl, pH 8.0). Immediately before use, 1mg of
NHS-LC-Biotin (Pierce) was dissolved in 50ml DMSO, mixed with
4ml buffer A, added to cells and incubated for 60min at 41C.
The cells were then washed five times with buffer A and after an
indicated time period solubilised in ice-cold RIPA buffer (1%
Triton X-100 and 1% deoxycholate in PBS) containing the
COMPLETE cocktail of protease inhibitors (Roche Diagnostics
GmbH, Mannheim, Germany) for 30min on ice. The extracts were
collected, cleared by centrifugation at 15000r.p.m. for 10min at
41C and stored at  801C. Protein concentrations in extracts were
quantified using the BCA protein assay reagent (Pierce, Rockford,
IL, USA).
For immunoprecipitation, MAb V/10 in a volume of 1ml culture
medium was bound to 25ml 50% suspension of Protein-A
Sepharose (Pharmacia, Uppsala, Sweden) for 2h at room
temperature. Biotinylated cell extract (200ml) or medium collected
from the cell culture (2ml) was precleared with 20ml of 50%
suspension of Protein-A Sepharose and then added to bound MAb.
Immunocomplexes collected on Protein-A Sepharose were washed
and separated by SDS–polyacrylamide gel (PAGE) gel (10%)
electrophoresis as described before (Zatovicova et al, 2003).
Afterwards, the proteins were transferred onto PVDF membrane,
revealed either with peroxidase-conjugated streptavidin (1:1000;
Pierce) or with biotin-labelled M75 followed by peroxidase-
conjugated streptavidin and visualised by enhanced chemilumi-
nescence.
ELISA
The capture antibody V/10 (10mgml
 1) was immobilised on the
surface of microplate wells overnight at 41C. After blocking and
washing, the cell extracts or media diluted in PBS were added to
the coated wells for an overnight binding at 41C. The attached
antigen was then allowed to react with biotinylated MAb M75
diluted 1:5000 (200ngml
 1) in PBS. The amount of bound
detector antibody was determined after 1h incubation with the
peroxidase-conjugated streptavidin (Pierce) using a peroxidase
substrate orthophenylene diamine (Sigma).
Immunofluorescence
Cells grown on glass coverslips were washed and kept in Ca
2þ-free
PBS for 20min to allow for their detachment. The remaining cells
were fixed in ice-cold methanol at  201C for 5min. Nonspecific
binding was blocked by incubation with PBS containing 1% BSA
for 30min at 371C. Then, the cells were incubated with M75
antibody for 1h at 371C followed by anti-mouse FITC-conjugated
horse antibody (Vector Laboratories, Burlingame, CA, USA)
diluted 1:300 in PBS–BSA for 1h at 371C. The nuclei were
stained with propidium iodide (Sigma). Finally, the coverslips were
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smounted onto slides in a mounting medium with Citifluor (Agar
Scientific Ltd, Essex, UK) and analysed by a confocal laser-
scanning microscope Fluoview Olympus IX 70. Images were
generated using Fluoview personal confocal microscope system
version 1.2 software.
RT–PCR
Total RNA was extracted from cells using NucleoSpin RNA II kit
(Macherey-Nagel, Du ¨ren, Germany). Precipitated RNA was dis-
solved in DEPC-treated water and reverse transcribed with the
M-MuLV reverse transcriptase (Finnzymes, Oy, Finland) using
random hexanucleotides as primers. PCR reactions were per-
formed using the primers listed in Table 1 and EXT DNA
polymerase (Finnzymes, Oy, Finland). Following an initial
denaturation at 951C for 3min, the amplification programme
was set as follows: denaturation at 951C for 30s, annealing at 58–
601C for 40s and extension at 721C during 40s for a total of 30
cycles, and finally 5min at 721C. The RT–PCR products were
analysed on a 2% agarose gel.
Zymography
Culture media were collected from the cells grown for 24h in
confluent monolayers, centrifuged (5000r.p.m. for 5min at 41C) to
remove cell debris and applied to a nonreducing SDS–PAGE
containing 0.1% collagen isolated from the rat tail. The electro-
phoresed gels were washed to remove SDS, renatured for 1h in
2.5% Triton X-100 at room temperature and incubated for 40h at
371C in the substrate buffer (50mM Tris-base, 0.2 M NaCl, 5mM
CaCl2,1mM ZnCl2, pH 7.6) to allow for the enzymes digesting the
collagen. After staining with 0.5% CBB, the gels were dried and
photographed.
RESULTS
Rate of basal CA IX ECD release
To analyse the rate of a basal shedding of CA IX ectodomain, we
used CGL3 hybrid cell line generated by fusion of HeLa cervical
carcinoma cells with normal human fibroblasts, which expresses
relatively high level of CA IX under standard cultivation conditions
(Zavada et al, 1993). The CGL3 cells grown in a confluent
monolayer for 24h were first labelled by biotinylation and then
chased for different time periods throughout the subsequent
48h. Level of CA IX present in the cellular extract and in the
corresponding culture medium was assessed by immunodetection
with two noncompetitive CA IX-specific MAbs directed to distinct
extracellular domains: M75 MAb against an N-terminal PG-like
domain and V/10 MAb against a juxtamembrane CA domain
(Figure 1A). Carbonic anhydrase IX was immunoprecipitated with
V/10 MAb and blotted onto the membrane. The membrane was
then treated either with the streptavidin–peroxidase to visualise
Table 1 List of the primers used for RT–PCR analysis of the metalloprotease expression in the human tumour cell lines
Sense primer Antisense primer
mRNA (GenBank accession no.) Position Sequence (50-30) Position Sequence (50-30)
MMP1 (NM_002421) 1293–1314 gatccaggttatcccaaaatga 1538–1517 caggaaaacaccttctttggac
MMP2 (NM_004530) 1002–1023 tgttcaatggcaaggagtacaa 1358–1339 ccaggaaagtgaaggggaag
MMP3 (NM_002422) 213–236 gtttgttaggagaaaggacagtgg 539–516 atatcagcctctccttcatacagc
MMP7 (BC003635) 196–217 agaagccaaactcaaggagatg 411–390 cgatccactgtaatatgcggta
MMP9 (NM_004994) 896–917 atcttccaaggccaatcctact 1082–1063 ccaggaaagtgaaggggaag
TIMP1 (BC007097) 11–32 gcgtggacatttatcctctagc 263–242 aaggtggtctggttgacttctg
TIMP2 (NM_003255) 2318–2339 atgggggttaggataggaagaa 2517–2496 ccgctgaatagaacaggctaag
MT1-MMP (X83535) 1249–1270 gcaaattcgtcttcttcaaagg 1476–1455 tgttcttggggtactcgctatc
TACE (NM_003183) 1612–1633 tggatgaaggagaagagtgtga 1874–1852 aagatccaagcaaacagtgtcat
b-Actin (NM_001101) 414–433 ccaaccgcgagaagatgacc 649–629 gatcttcatgaggtagtcagt
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Figure 1 Basal carbonic anhydrase IX (CA IX) ectodomain shedding
from CGL3 cells. (A) Schematic illustration of CA IX molecule with an
extracellular portion composed of N-terminal proteoglycan (PG)-like
region and central carbonic anhydrase (CA) domain linked via a single
transmembrane segment to a short intracytoplasmic (IC) tail. Detection of
the ectodomain was enabled by two noncompetitive CA IX-specific
monoclonal antibodies: V/10 directed to CA and M75 directed to PG. The
arrow indicates a putative cleavage site whose exact position is unknown.
(B) CA IX ECD release was analysed by immunoprecipitation–
immunoblotting analysis of the aliquots of nondiluted extracts (ex) and
media (m) corresponding to the same number of cells obtained from the
biotinylated CGL3 cultures that were chased for various time periods. CA
IX was first precipitated with V/10 MAb, blotted and revealed with
streptavidin–peroxidase. (C) The same blot was stripped and reprobed
with the biotinylated M75 followed by streptavidin–peroxidase. (D)C AI X
ECD release from biotinylated CGL3 cells was assessed also by sandwich
ELISA using V/10 antibody as a capture and streptavidin–peroxidase as a
detector. For this purpose, cell extracts were diluted 20 times, whereas
media were diluted 1:2. OD492 values represent average levels of CA IX
measured in triplicates in at least three independent experiments, and
standard deviations are indicated. (E) CGL3 cells grown on glass coverslips
were allowed to detach in Ca
2þ-free PBS and then subjected to
immunofluorescence labelling with M75 and FITC-conjugated anti-mouse
antibodies. The cell nuclei were stained with propidium iodide. The arrow
points to CA IX-positive ‘traces’ left after the detachment of CGL3 cell.
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sonly the biotin-labelled fraction of the protein actually expressed at
the beginning of the shedding period (Figure 1B) or with biotin-
labelled M75 followed by streptavidin–peroxidase to visualise also
the protein synthesised de novo and shed during the chase
(Figure 1C). Both approaches showed that the proportion of the
released CA IX ECD compared to the cell-bound protein is rather
low and the process of basal shedding is relatively slow. Molecular
weight of the CA IX ECD was decreased by about 4kDa compared
to the full-length CA IX protein and this reduction corresponded
roughly with the calculated mass of the removed TM and IC
regions. The basal shedding of CA IX ECD was also analysed by
ELISA, based on the same principle as the immunoprecipitation-
immunoblotting experiment described on Figure 1B. Resulting
absorbance values were in accord with the levels of CA IX seen on
the blot and showed that CA IX accumulation in the medium
is accompanied by a reduced amount of the cell-bound protein
(Figure 1D). Interestingly, CA IX ECD was detectable not only in
the medium, but it was regularly observed on the coverslips after
detachment of nonfixed, viable CA IX-positive cells before their
immunofluorescence labelling with anti-CA IX antibodies. Carbo-
nic anhydrase IX-specific signal in the form of the ‘cell traces’ was
clearly visible in CGL3 culture in the absence of the cell body
including nucleus (Figure 1E). This finding indicated that CA IX
was shed from the entire surface of tumour cells including the
ventral side contacting the solid support.
Shedding of CA IX ECD in various cell lines under
normoxia and hypoxia
The level of CA IX expression considerably varies in different cell
lines, thus raising a question whether the basal ectodomain
shedding reflects abundance of the CA IX protein in the cells or
whether there are any cell-type-related variations. To answer this
question, we examined several tumour cell lines that naturally
express CA IX and two transfected cell lines with a constitutive
ectopic CA IX expression (MDCKþCA IX and C33aþCA IX) for
their capacity to shed CA IX ECD. The cells were grown in a
confluent monolayer and ECD release was evaluated after a
shedding period of 48h. Extracts and media were added to V/10
MAb-coated wells and bound CA IX was detected with biotin-
labelled M75 MAb followed by streptavidin–peroxidase. As shown
in Figure 2A, ECD levels generally corresponded to levels of the
cell-bound CA IX protein, so that the cells with a high CA IX
expression such as CGL3, HeLa, HT-29 and both transfectants
displayed relatively high levels of ECD and the cells with a low CA
IX expression such as CGL1 and ACHN released correspondingly
less ECD. The production of CA IX ECD was slightly lower in SiHa
cells and in C33aþCA IX transfectants when compared to the
other examined cell lines. More thorough assessment of the
quantitative relationships between the cellular and shed CA IX in
ELISA with titration of the extracts and media from the cells with
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Figure 2 Basal rate of carbonic anhydrase IX (CA IX) ectodomain release from various cell lines under normoxia and hypoxia. (A) Confluent monolayers
of CA IX-expressing cells were washed, fresh medium was added and the shedding was allowed to proceed over a 48-h period. The media were collected,
the cells were extracted and the content of CA IX was determined by ELISA with V/10 as a capture and biotinylated M75 followed by streptavidin–
peroxidase as a detector. (B) Serial dilutions of the extracts and media were examined by ELISA to relate the cellular and extracellular CA IX
concentrations. (C) The parallel cultures were maintained for 48h in normoxia and hypoxia (2% O2). Harvested media (diluted 1:2) and cell extracts
(diluted 1:20) were assayed in ELISA and the hypoxia-induced changes of CA IX levels in the cells and released to medium were illustrated as a ratio
between the absorbance values measured in the hypoxic samples and the values of the corresponding normoxic samples. *Po0.01 and **Po0.001 by
Student’s t-test.
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shigh, low and constitutive CA IX expression, respectively, showed
that the proportion of the released CA IX ECD is close to 10% in all
three cases (Figure 2B). This finding supports the idea that the
basal CA IX shedding is a steady process that operates in different
cells to cleave off an approximately same fraction of the CA IX
molecules.
Expression of CA IX is strongly induced by hypoxia in an HIF-1-
dependent manner (Wykoff et al, 2000). This induction results in a
highly increased abundance of CA IX protein in the hypoxic cells
both in culture and in tumour tissues (Potter and Harris, 2003). In
addition, hypoxia can improve a catalytic capacity of CA IX to
acidify extracellular pH (Svastova et al, 2004). However, it is not
known whether and how hypoxia influences the shedding of CA IX
ECD. Therefore, we measured the amounts of the cellular CA IX
and ECD in extracts and media from the cells exposed to hypoxia
(2% O2) for 48h. Hypoxic treatment of CGL3 and CGL1 cells led to
increased cellular levels of CA IX accompanied by accordingly
elevated production of an extracellular CA IX ECD, whereas ECD
accumulation was lower in SiHa and HT-29 cells compared to their
cellular CA IX (Figure 2C). Nevertheless, hypoxic shedding of
CA IX ECD in the transfected cells that constitutively express
CA IX from SV40 promoter remained similar to shedding under
normoxic conditions, suggesting that the rate of the basal CA IX
shedding was principally not affected by hypoxia.
Inhibition of basal CA IX ECD shedding by BB-94
Numerous cell-surface proteins are shed by a mechanism that
involves metalloproteases, particularly the matrix metalloproteases
and members of the ADAM family of proteins. The activity of these
proteases is sensitive to BB-94 inhibitor (batimastat). Therefore,
we used this inhibitor to treat the cells and see whether it can
influence the shedding of CA IX. Immunoblotting of CA IX protein
immunoprecipitated from CGL3 cells grown in the presence of BB-
94 revealed a considerably reduced production of the CA IX ECD
(Figure 3A). This finding was confirmed by sandwich ELISA,
which showed that 1mM BB-94 inhibited CA IX ECD shedding to
about half of the control value. Similar reduction was observed in
other three cell lines, namely CGL1 and transfected C33aþCA IX
as well as MDCKþCA IX cells, and appeared comparable under
hypoxia (Figure 3B). Moreover, ECD shedding was inhibited by
BB-94 in a concentration-dependent manner in CA IX-transfected
MDCK cells where 10mM BB-94 decreased the level of ECD to less
than a tenth of a control value (Figure 3C).
Regulated shedding of CA IX ECD
Shedding of cell-surface proteins is often accelerated via a signal
transduction triggered by phorbol esters (such as PMA),
pervanadate (V2O7) or serum growth factors. Depending on a
type of the stimulus, shedding machinery involves either protein
kinase C (PKC)-related or -unrelated pathways (Arribas et al,
1996). In order to find out whether CA IX ECD release can be
regulated, we examined the effects of serum, EGF, PMA and
pervanadate on the cell-bound and extracellular level of CA IX. To
analyse the CA IX shedding in the presence and absence of serum,
we first starved the cells in serum-free medium for 24h and then
added fresh medium containing either 10% FCS or no FCS for
additional 24h. As shown in Figure 4A, serum did not affect the
release of CA IX ECD in any of the examined cell lines that
naturally express CA IX, except SiHa, where it increased the cell-
associated fraction of CA IX but not the ECD shedding. The lack
of effect was also observed in MDCKþCA IX cells incubated in
the presence or absence of either serum or EGF alone. In contrast,
PMA was able to increase the level of CA IX ECD produced in
CGL3, SiHa and HT-29 cells throughout 24h (Figure 4B). A strong
induction of CA IX shedding by PMA was observed in the
transfected MDCKþCA IX cells already after 2h (Figure 4C). Even
higher production of CA IX ECD was induced by pervanadate,
and the addition of PMA to pervanadate led to further increase
(Figure 4D). Induced shedding could be inhibited by BB-94,
suggesting a metalloprotease involvement also in the regulated
cleavage of CA IX ECD. It is worth noting that both PMA and
pervanadate stimulated also a formation of the ‘cell traces’, as
revealed by the more intense immunofluorescence signal found
on the glass coverslips after stripping off the treated CGL3 cells
(Figure 4E). This finding supported the idea that the traces
resulted from the shedding process similar to the release of CA IX
ECD to a medium above the culture.
Relationship between CA IX ECD release and expression of
metalloproteases
Although the shedding machinery involves several common
components, different cell-surface proteins can be cleaved by
different metalloproteases. The enzyme–substrate relationship is
determined in part by a spectrum of metalloproteases available in
the particular cell/tissue type. Therefore, we were interested to look
at the repertoire of metalloproteases, which are known to mediate
24 h 48 h
BB-94
CA IX
ex m ex m ex m ex m
ECD
++ ++
Normoxia
CGL3 CGL1 C33a MDCK
+CA IX +CA IX
CGL3 CGL1 C33a MDCK
+CA IX +CA IX
Hypoxia
24 h treatment 6 h treatment
CA IX ECD
1.0
0.5
0.0
151 0 151 0
BB-94(g ml–1) 
1.0
0.5
0.0
B
B
-
9
4
/
c
o
n
t
r
o
l
B
B
-
9
4
/
c
o
n
t
r
o
l
∗ ∗ ∗∗ ∗∗ ∗ ∗ ∗∗ ∗∗
A
B
C
Figure 3 Inhibition of the basal carbonic anhydrase IX (CA IX) shedding
with BB-94 metalloprotease inhibitor. (A) CGL3 cells were biotinylated
and then allowed to shed CA IX ECD in the presence and absence of 1mM
BB-94. The media (m) were collected, the cells were extracted (ex) and
the corresponding aliquots of the materials were analysed by immuno-
precipitation–immunoblotting as described in Figure 1c. (B) ELISA was
used to determine the inhibition of CA IX shedding with 1mM BB-94. The
cells were treated for 24h throughout their incubation in normoxia or
hypoxia. Extent of inhibition was illustrated as a ratio of the absorbance
values of the materials from BB-94-treated cells vs their nontreated
counterparts normalised according to total protein concentrations.
(C) ELISA assessment of a BB-94 concentration-dependent inhibition of
CA IX ECD release in MDCKþCA IX cells. The results are expressed as a
ratio between the BB-94-inhibited and control samples. *Po0.01 and
**Po0.001 by Student’s t-test.
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sshedding of important regulatory proteins, in our human cell
models. RT–PCR analysis revealed that MMP1 and MMP9 are not
expressed in any of the five cell lines that shed CA IX ECD. MMP 2,
3, 7 and MT1-MMP were absent from at least one of these cell lines
(Figure 5A). In accord, the cell lines lacking expression of MMP1,
-2 and -9 also failed to show the activity of the corresponding
collagenases in zymography (Figure 5B). This fact disqualified
the above-mentioned enzymes as potential governors of CA IX
shedding. On the other hand, TACE (ADAM17) was the only
examined metalloprotease whose expression could be detected in
all cell lines that produce CA IX ECD (Figure 2A and C). Since
TACE is well known as a molecule implicated in the shedding
of many proteins, we decided to follow this clue in our further
experiments.
CA IX ECD shedding in CHO-M2 cells
To evaluate a possible role of TACE in the cleavage of CA IX ECD,
we examined the CA IX shedding in CHO-M2 cells that are
defective in many TACE-mediated shedding events due to
inactivating mutations causing its accumulation in the early
secretory pathway (Villanueva de la Torre et al, 2004). Parental
wild-type CHO-WT cells and CHO-M2þTACE transfectants
expressing a functional TACE were used for comparison. In
addition, we also employed CHO-Ka13 cells deficient in HIF-1a
(Wood et al, 1998). All cell lines were plated to form semiconfluent
monolayers and transiently transfected with a pSG5C-CA9
plasmid. Next day, the transfected monolayers were thoroughly
washed, fresh medium was added and the cells were subjected to
normoxia or hypoxia for 24h. Sandwich ELISA revealed that the
transfection resulted in very similar expression levels of CA IX
in all cell lines. In addition, basal shedding of CA IX ECD was
comparable in WT, M2 and Ka13 cells and was a little higher in the
cells with reconstituted TACE (Figure 6A).
In some cases described earlier in the literature, TACE was
not critical for the constitutive shedding, but was required for
its activation. Therefore, we also analysed the level of CA IX
ECD produced by the transfected CHO-WT, CHO-M2 and
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Figure 4 Activation of carbonic anhydrase IX (CA IX) ectodomain release by phorbol-12-myristate-13-acetate (PMA) and pervanadate. (A) The cells
were first serum starved and then incubated with fresh medium in the presence or absence of 10% FCS, or alternatively in the presence or absence of
epidermal growth factor (EGF), for 24h. The extracts and media were analysed by ELISA and the results were illustrated as a ratio between the stimulated
and nonstimulated cells. (B) The serum-starved cells were allowed to release CA IX ECD upon treatment with PMA for 24h. The extracts and media were
analysed by ELISA as above. (C) MDCKþCA IX cells were maintained overnight in serum-free medium and then treated for 2h with PMA. Activation of
CA IX shedding was revealed by immunoprecipitation–immunoblotting of the corresponding aliquots of the cell extracts and media similarly as in Figure 1.
(D) MDCKþCA IX cells were serum-starved and then treated with PMA and/or pervanadate (V2O7) for 2h. BB-94 was added 30min before the
induction. Collected media and cell extracts were assayed in ELISA and the results were illustrated as a ratio between the normalised absorbance data
obtained from treated and control samples. (E) CGL3 cells grown on glass coverslips were serum-starved and then treated with PMA and pervanadate for
2h. After allowing detachment of cells in Ca
2þ-free PBS, the coverslips were labelled with M75 followed by FITC-conjugated anti-mouse antibodies and the
cell nuclei were stained with propidium iodide. The arrows indicate CA IX-positive ‘cell traces’. *Po0.01 and **Po0.001 by Student’s t-test.
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found that CHO-M2 cells were unable to activate cleavage of CA IX
ECD, whereas CHO-WT and CHO-M2þTACE showed signifi-
cantly increased shedding with both inducing factors, which was
considerably reduced by BB-94 (Figure 6B). This observation
strongly suggested that the regulated CA IX shedding is a TACE-
dependent process.
DISCUSSION
In the present study, we brought the evidence that the
transmembrane carbonic anhydrase isoform CA IX, which is
predominantly expressed in tumour cells in response to hypoxia, is
shed to extracellular space in a metalloprotease-dependent
manner. On this basis, CA IX can be classified among those
regulatory proteins whose abundance on the cell surface and/or in
the cell microenvironment is controlled via a metalloprotease-
mediated ectodomain release, such as c-ErbB2, c-ErbB4, pro-EGF,
CD44, c-Met, E-cadherin and others (Vecchi et al, 1998; Codony-
Servat et al, 1999; Noe et al, 2000; Kajita et al, 2001; Nath et al,
2001; Le Gall et al, 2003). Basal shedding of CA IX ECD is rather
inefficient, accounting for approximately 10% of the total CA IX
(corresponding to about 20% of the membrane-bound protein,
data not shown) as determined by ELISA in several tumour cell
lines with natural expression of CA IX as well as in the transfected
cells that constitutively produce ectopic CA IX. However, this is
not unusual since a similarly low or even lower basal rate of ECD
release was described for c-Erb2, E-cadherin and c-Met (Codony-
Servat et al, 1999; Noe et al, 2000; Nath et al, 2001). These
molecules elicit their function principally via signalling across the
cell membrane and therefore it seems logical that the plasma
membrane is their primary site of residence.
Hypoxia increases the expression of CA IX to a variable degree
depending on a cell type. Interestingly, the cells with a low
normoxic level of CA IX (CGL1 and SiHa) generally show high
induction, whereas the cells with high normoxic level (CGL3 and
HT-29) are less responsive. It appears that there exists certain
maximum of CA IX achievable by the hypoxic induction that
might be useful or required for a proper cell functioning in low
oxygen conditions, namely for the control of intra- and
extracellular pH and modulation of cell adhesion (Svastova et al,
2003, 2004). Shedding of CA IX in hypoxia generally follows an
increase in total protein levels, so that the proportion of ECD
relative to cellular CA IX remains the same. This may indicate that
hypoxic cells have to cleave an increased number of the substrate
CA IX molecules and it is well possible that a level or activity of a
relevant ‘sheddase’ is enhanced by hypoxia. As a result, hypoxia
simultaneously raises the cellular and extracellular content of CA
IX while maintaining the normal basal rate of shedding. Although
the biological consequences of the elevated amount of CA IX ECD
produced from hypoxic tumour cells are unknown, this fact may
have a practical value. Assessment of CA IX ECD in serum could
provide information on the presence of hypoxic tumours and
might be of a prognostic relevance. Data supporting this
assumption are still missing; nevertheless, the recently published
paper of Zavada et al (2003) demonstrating elevated CA IX ECD in
the serum of patients with renal cell carcinomas, which frequently
upregulate CA IX due to inactivating mutation of VHL tumour
suppressor gene and constitutive activation of HIF-1, suggests that
the idea is meaningful.
Basal rate of CA IX ECD release is not affected by serum growth
factors, but can be greatly enhanced by PMA and pervanadate.
This effect is clearly visible in the transfected cells that express CA
IX from the constitutive promoter that allows for elimination of
the transcriptional responses to inducing factors. Therefore, any
PMA- or pervanadate-triggered change in the level of extracellular
CA IX can be attributed to ECD shedding efficiency. Induction of
shedding is much stronger in permanently transfected MDCK-CA
IX cells compared to transiently transfected CHO-WT, possibly
due to a higher susceptibility of MDCK cells to treatment and/or
better activation of the phosphorylation signalling. Indeed, such
cell-type-related differences can also be found in several studies
cited herein. It is worth noting that CA IX ECD cleavage is more
induced in the cells treated with pervanadate, a potent protein-
tyrosine phosphatase inhibitor, than in the cells incubated in the
presence of PMA, which is known to stimulate PKC. The addition
of PMA can increase the pervanadate-activated release of CA IX
ECD pointing out to parallel pathways that appear to involve
transmission of the phosphorylation signals and encompass PKC
as one of active components. This type of activation distinguishes
CA IX ECD cleavage from some other cases of regulated shedding,
such as c-ErB2, whose cleavage is induced by pervanadate and not
by PMA (Codony-Servat et al, 1999), or pro-EGF and c-ErbB4 that
are increasingly shed in response to PMA, pervanadate as well as to
withdrawal or addition of growth factors (Vecchi et al, 1998; Le
Gall et al, 2003). Although the precise molecular mechanism of
regulated CA IX shedding has not been investigated so far, these
initial data indicate that certain physiological situations associated
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Figure 5 Expression of metalloproteases in selected human tumour cell
lines and related collagenase activities. The cells were grown in serum-free
media for 48h. The media were collected for a collagen zymography and
the cells were utilised as a source of RNA for RT–PCR. (A) Expression of
metalloproteases was analysed by RT–PCR using the gene-specific primers
listed in Table 1. b-Actin was used as a standard to monitor the amount
of RNA templates. (B) Media were applied to a collagen-containing
SDS–PAGE and collagenase activities of MMP1, -2 and -9 were evaluated
according to an intensity of the nonstained zones representing a digested
collagen. Medium from HT1080 fibrosarcoma cells was used as a positive
control rich for MMP2 and -9.
Metalloprotease-dependent shedding of CA IX ectodomain
M Zatovicova et al
1273
British Journal of Cancer (2005) 93(11), 1267–1276 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
swith signalling events may require either quick removal of CA IX
from the cell surface or rapid release of higher amount of CA IX
ECD to the extracellular milieu. In this respect, it is worth
mentioning that both PMA and pervanadate stimulate the
shedding of CA IX ECD from the ventral side of cells to their
adhesive support, which results in the formation of intense ‘cell
traces’ that are very similar to traces formed by the proteolytic
release of aVb3-integrin from the stressed tumour cells (Majda
et al, 1994). This finding of a so far unclear significance is not
incompatible with the proposed role of CA IX in cell adhesion
(Zavada et al, 2000). However, better understanding of this
phenomenon requires further experimental efforts.
Involvement of metalloprotease(s) in the basal shedding of CA
IX has been suggested by a capacity of hydroxamate-based broad-
spectrum metalloprotease inhibitor BB-94 to block this process
under both normoxia and hypoxia in a concentration-dependent
manner and in different cell lines. In addition, BB-94 can also
inhibit activated CA IX shedding triggered by both PMA and
pervanadate, indicating that it is regulated by metalloproteases
responsive to both PKC-dependent and -independent signals. The
putative ‘sheddase’ responsible for the basal CA IX ECD cleavage
still awaits identification, since our attempts to make a deduction
from the expression pattern of the most obvious candidates did
not lead to any clear resolution. However, from our experiments
performed with mutant CHO-M2 cells defective in shedding of
many unrelated cell surface molecules due to inactivating mutation
and impaired biogenesis of TACE/ADAM17 (Li and Fan, 2004;
Villanueva de la Torre et al, 2004), it appears that TACE is not the
main regulator/executor of the basal CA IX shedding. Nevertheless,
it is possible that TACE can contribute to the constitutive cleavage
of CA IX, because the ECD shedding in CHO-M2-TACE-
transfected cells that express a functional TACE was somewhat
higher than in TACE-defective CHO-M2 cells. Indeed, CHO-M2
cells are unable to activate CA IX ECD release in response to
stimulation by PMA and pervanadate, whereas this activation is
restored in TACE-transfected CHO-M2 cells, so TACE is clearly a
proteolytic component of the regulated CA IX shedding. This
feature of CA IX is reminiscent of b-amyloid protein, L selectin,
IL-6 receptor, pro-TGFa and TNFa that all need TACE for
activated release of their extracellular portions (Arribas et al,
1996; Li and Fan, 2004; Villanueva de la Torre et al, 2004). Taking
these facts together, liberation of CA IX ectodomain appears to
include at least two distinct metalloproteases, which play a role in
different situations that may require either a constant supply of CA
IX ECD or its fast and high input to extracellular space.
Irrespective of the molecular mechanism(s) behind the CA IX
shedding, it is now clear that CA IX ECD is not just a remnant of
unscheduled degradation, but it is a product of an active and
regulated process driven by metalloproteases. At this moment, it is
difficult to anticipate a biological function of the released ECD. The
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Figure 6 Role of TACE/ADAM17 in the basal and regulated cleavage of carbonic anhydrase IX (CA IX) ECD. CHO-wild type (WT) cells, their mutated
variant CHO-M2 defective in TACE/ADAM17 maturation, CHO-M2þTACE transfectants containing a fully functional TACE and CHO-Ka13 cells lacking
HIF-1a were transiently transfected to express CA IX. (A) The transfected cells were allowed to shed CA IX into the medium over 24-h incubation period
under normoxia and hypoxia (2% O2). The same procedure was applied to mock-transfected cells. Media and extract collected from all dishes were assayed
by ELISA. The results were expressed as average absorbance values with standard deviations. (B) The transfected cells were treated for 2h either with PMA
or with pervanadate in the absence and presence of BB-94 metalloprotease inhibitor added 30min before the treatment. The results were illustrated as a
ratio between the absorbance data obtained from the induced vs control samples. *Po0.01 and **Po0.001 by Student’s t-test.
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sliterature offers various examples from activated growth factors
through receptor ligands toward soluble receptors regulating
cellular processes via autocrine or paracrine effects (Werb and
Yan, 1998). Thinking in terms of CA IX expression pattern and its
proposed roles in tumour cells (Svastova et al, 2003, 2004;
Robertson et al, 2004), it is likely that CA IX ECD may either
interfere or cooperate with the full-length protein expressed on the
cell surface, presumably by means of interactions with its binding
partners. One obvious possibility would be a competitive binding
of CA IX ECD to extracellular portion of anion exchanger
molecules to modulate their bicarbonate transport efficiency and
thereby affect the regulation of intracellular and extracellular pH
in tumours, depending on actual physiological conditions and
complex status of signal transduction. Although a recent finding of
a direct interaction of anion exchangers with the full-length CA IX
protein as well as with its engineered extracellular portion similar
to ECD supports this idea (Morgan et al, 2005),
additional extensive investigation is needed to shed light on the
functional implications of the CA IX shedding and then devise
strategies for its manipulation potentially leading to reduced
tumour growth.
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